Tonix Pharmaceuticals Sets Nov. 9 Call for Q3 2026 Results as Fibromyalgia Launch and CNS Pipeline Advance
Found this article helpful?
Share it with your network and spread the knowledge!
Tonix Pharmaceuticals Holding Corp., a fully integrated, commercial-stage biotechnology company, will host a conference call and webcast on Monday, Nov. 9, 2026, at 8:30 a.m. ET to report third-quarter 2026 financial results and operational highlights, according to a company announcement. Investors and interested parties can register to participate in the call or view the webcast through the company, and a replay will be available under “IR Events” in the Investors section of the Tonix website. The full press release is available through this link, and ongoing updates on Tonix Pharmaceuticals (NASDAQ: TNXP) are posted in the company’s newsroom at https://nnw.fm/TNXP.
The quarterly update matters because Tonix is no longer only a clinical-stage story. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. For investors and industry observers, the Nov. 9 call is an early checkpoint on whether that commercial build-out is translating into traction, and for patients and clinicians it marks the arrival of a new option in a condition that has long gone underserved.
Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Beyond CNS, Tonix is advancing immunology programs including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company notes that its product development candidates are investigational new drugs or biologics and that their efficacy and safety have not been established and they have not been approved for any indication.
The announcement reached investors through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, delivering wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. Full terms of use and disclaimers are available on the NetworkNewsWire website at https://www.NetworkNewsWire.com/Disclaimer.